Jieqi Tu

Dr. Jieqi Tu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
GCGeorgia Chen
Georgia Chen
CZChao Zhang
Chao Zhang
JCJianhong Chen
Jianhong Chen
DWDongsheng Wang
Dongsheng Wang
JTJieqi Tu
Jieqi Tu
Zhong ChenZhong Chen
Zhong Chen
FAT1 is frequently mutated in head and neck squamous cell carcinoma (HNSCC), but the biological and clinical effects of FAT1 mutations in HNSCC remain to be fully elucidated. We investigated the landscape of altered protein and gene expression associated with FAT1 mutations and clinical outcomes of patients with HNSCC. FAT1 mutation was stratified with clinical information from The Cancer Genome Atlas HNSCC databases with more than 200 proteins or phosphorylated sites. FAT1 mutation was significantly more prevalent among HPV(−), female, and older patients and was enriched in oral, larynx, and hypopharynx primary tumors. FAT1 mutation was also significantly associated with lower FAT1 gene expression and increased protein expression of HER3_pY1289, IRS1, and CAVEOLIN1. From an independent International Cancer Genome Consortium dataset, FAT1 mutation in oral cancer co-occurred with top mutated genes TP53 and CASP8. Poorer overall survival or progression-free survival was observed in patients with FAT1 mutation or altered HER3_pY1289, IRS1, or CAVEOLIN1. Pathway analysis revealed dominant ERBB/neuregulin pathways linked to FAT1 mutations in HNSCC, and protein signature panels uncovered the heterogeneity of patient subgroups. Decreased pEGFR, pHER2, and pERK and upregulated pHER3 and HER3 proteins were observed in two FAT1 knockout HNSCC cell lines, supporting that FAT1 alterations lead to altered EGFR/ERBB signaling. In squamous cancers of the lung and cervix, a strong association of FAT1 and EGFR gene expressions was identified. Collectively, these results suggest that alteration of FAT1 appears to involve mostly HPV(−) HNSCC and may contribute to resistance to EGFR-targeted therapy.Significance: Integrative bioinformatics and statistical analyses reveal a panel of genes and proteins associated with FAT1 mutation in HNSCC, providing important insights into prospective clinical investigations with targeted therapies.

7 October 2023 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Open access
SBSumit Bhattacharyya
Sumit Bhattacharyya
IOInsug O-Sullivan
Insug O-Sullivan
JTJieqi Tu
Jieqi Tu
ZCZhengjia Chen
Zhengjia Chen
JTJoanne Tobacman
Joanne Tobacman
In the syngeneic, subcutaneous B16F10 mouse model of malignant melanoma, treatment with exogenous ARSB markedly reduced tumor size and extended survival. In vivo experiments showed that local treatment with exogenous N-acetylgalactosamine-4-sulfatase (Arylsulfatase B; ARSB) led to reduced tumor growth over time (p < 0.0001) and improved the probability of survival up to 21 days (p = 0.0391). Tumor tissue from the treated mice had lower chondroitin 4-sulfate (C4S) content and lower sulfotransferase activity. The free galectin-3 declined, and the SHP2 activity increased, due to altered binding with chondroitin 4-sulfate. These changes induced effects on transcription, which were mediated by Sp1, phospho-ERK1/2, and phospho-p38 MAPK. Reduced mRNA expression of chondroitin sulfate proteoglycan 4 (CSPG4), carbohydrate sulfotransferase 15 (N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase), and matrix metalloproteinases 2 and 9 resulted. Experiments in the human melanoma cell line A375 demonstrated similar responses to exogenous ARSB as in the tumors, and inverse effects followed ARSB siRNA. ARSB, which removes the 4-sulfate group at the non-reducing end of C4S, acts as a tumor suppressor, and treatment with exogenous ARSB impacts on vital cell signaling and reduces the expression of critical genes associated with melanoma progression.

28 November 2022 in Statistics in Medicine
Verified
Journal Article
Open access
JTJieqi Tu
Jieqi Tu
JSJiehuan Sun
Jiehuan Sun
The shared random effects joint model is one of the most widely used approaches to study the associations between longitudinal biomarkers and a survival outcome and make dynamic risk predictions using the longitudinally measured biomarkers. Various types of joint models have been developed under different settings in the past decades. One major limitation of joint models is that they could be computationally expensive for complex models where the number of the shared random effects is large. Moreover, the inferential accuracy of joint models could also be diminished for complex models due to approximation errors. However, complex models are frequently needed in practice, for example, when the longitudinal biomarkers have nonlinear trajectories over time or the number of longitudinal biomarkers of interest is large. In this article, we propose a novel Gaussian variational approximate inference approach for fitting joint models, which significantly improves computational efficiency while maintaining inferential accuracy. We conduct extensive simulation studies to evaluate the performance of our proposed method and compare it to existing methods. The performance of our proposed method is further demonstrated on a dataset of patients with primary biliary cirrhosis.


16 November 2024 in Journal of Biopharmaceutical Statistics
Verified
Journal Article
Closed access
HSHao Sun
Hao Sun
HLHsin-Yu Lin
Hsin-Yu Lin
JTJieqi Tu
Jieqi Tu
RARevathi Ananthakrishnan
Revathi Ananthakrishnan
EKEunhee Kim
Eunhee Kim
Traditional phase I dose finding cancer clinical trial designs aim to determine the maximum tolerated dose (MTD) of the investigational cytotoxic agent based on a single toxicity outcome, assuming a monotone dose-response relationship. However, this assumption might not always hold for newly emerging therapies such as immuno-oncology therapies and molecularly targeted therapies, making conventional dose finding trial designs based on toxicity no longer appropriate. To tackle this issue, numerous early-phase dose finding clinical trial designs have been developed to identify the optimal biological dose (OBD), which takes both toxicity and efficacy outcomes into account. In this article, we review the current model-assisted dose finding designs, BOIN-ET, BOIN12, UBI, TEPI-2, PRINTE, STEIN, and uTPI to identify the OBD and compare their operating characteristics. Extensive simulation studies and a case study using a CAR T-cell therapy phase I trial have been conducted to compare the performance of the aforementioned designs under different possible dose-response relationship scenarios. The simulation results demonstrate that the performance of different designs varies depending on the particular dose-response relationship and the specific metric considered. Based on our simulation results and practical considerations, STEIN, PRINTE, and BOIN12 outperform the other designs from different perspectives.

22 June 2025 in Sensors
Verified
Journal Article
Open access
PDF file
NTNathan Tintle
Nathan Tintle
JTJieqi Tu
Jieqi Tu
ALAnna Luong
Anna Luong
SMShina Min
Shina Min
Kiarri KershawKiarri Kershaw
Kiarri Kershaw
UBUlf Gunnar Bronas
Ulf Gunnar Bronas
The use of sensors in mobility, health, and place research is rapidly increasing, with the promise of objective quantification of human behavior patterns and the ability to understand complex patterns of human behavior in ways that were previously impossible. However, there is now a critical bottleneck in managing the resulting influx of sensor data. In particular, limited software pipelines exist that both clean and harmonize global positioning system (GPS) and accelerometer data into a single dataset that integrates information about time, space, and movement. Other approaches are costly due to proprietary software, personnel time, and being prone to human errors. To address this gap, we have created the open source AGPSR pipeline in the R software environment, combining GPS and accelerometer data to yield simultaneous information on location and activity status. Demonstrations of the pipeline and validity data are presented. The AGPSR software (Ver 1.0) is now available for researchers to use in studies involving simultaneous GPS and accelerometer wear.